FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).
Croatian: Liječenje duboke venske tromboze (DVT) i plućne embolije (PE) te prevencija ponavljajućih DVT i PE u odraslih (vidjeti dio 4.4 za hemodinamski nestabilne bolesnike s PE).
English: • The other ingredients are: - Tablet core: lactose anhydrous, microcrystalline cellulose, croscarmellose sodium, sodium laurilsulfate, magnesium stearate (E470b).
Croatian: • Drugi sastojci su: Jezgra tablete: bezvodna laktoza, mikrokristalična celuloza, umrežena karmelozanatrij, natrijev laurilsulfat, magnezijev stearat (E470b).
English: - medicines for high blood pressure or heart problems (e.g., diltiazem) - antidepressant medicines called selective serotonin re-uptake inhibitors or serotonin norepinephrine re-uptake inhibitors
Croatian: - lijekovi za liječenje visokog krvnog tlaka ili srčanih tegoba (npr. diltiazem) - lijekovi za liječenje depresije koji se nazivaju inhibitorima ponovne pohrane serotonina ili inhibitori ponovne pohrane serotonina i noradrenalina
English: Apixaban is a substrate of transport proteins, P-gp and breast cancer resistance protein (BCRP).
Croatian: Apiksaban je supstrat transportnih proteina: P-gp i proteina koji uzrokuje rezistenciju raka dojke na lijekove (engl. breast cancer resistance protein, BCRP).
English: A calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and emergency surgery (prothrombin time (PT), international normalized ratio (INR) and activated partial thromboplastin time (aPTT) clotting tests are not recommended) - see SmPC.
Croatian: Kalibrirano kvantitativno određivanje sadržaja anti-faktora Xa može biti korisno u iznimnim situacijama, primjerice kod predoziranja i hitnih operacija (testovi zgrušavanja: protrombinsko vrijeme (PV), međunarodni normalizirani omjer (INR) i aktivirano parcijalno tromboplastinsko vrijeme (aPTV) se ne preporučaju) - vidjeti sažetak opisa svojstava lijeka.
English: Therefore Eliquis should be used with caution in this population (see sections 4.4 and 5.2).
Croatian: Stoga se u navedenoj populaciji Eliquis treba primjenjivati uz oprez (vidjeti dijelove 4.4 i 5.2).
English: Table 3 below shows the predicted steady state exposure and anti-Factor Xa activity for each indication.
Croatian: Tablica 3 u nastavku pokazuje predviđenu izloženost u stanju dinamičke ravnoteže i anti-faktor Xa aktivnost za svaku indikaciju.
English: For patients undergoing catheter ablation for atrial fibrillation, Eliquis treatment does not need to be interrupted (see sections 4.2, 4.3 and 4.5).
Croatian: U bolesnika koji će biti podvrgnuti kateterskoj ablaciji za fibrilaciju atrija nije potrebno prekinuti liječenje lijekom Eliquis (vidjeti dijelove 4.2, 4.3 i 4.5).
English: - Necessity to carry the Patient alert card with them at all times
Croatian: - Nužnosti da sa sobom uvijek nose Karticu s upozorenjima za bolesnika
English: Eliquis has not been shown to impair your ability to drive or use machines.
Croatian: Eliquis ne utječe na sposobnost upravljanja vozilima i rukovanja strojevima.
English: To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs
Croatian: Za liječenje krvnih ugrušaka u venama nogu i krvnih ugrušaka u krvnim žilama pluća
English: Apixaban is not recommended for the treatment of DVT and PE in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp since efficacy may be compromised (see section 4.4).
Croatian: Apiksaban se ne preporučuje u liječenju DVT i PE u bolesnika koji istodobno primaju sistemsku terapiju snažnim induktorima CYP3A4 i P-gp, jer se može ugroziti djelotvornost (vidjeti dio 4.4).
English: After combined administration of enoxaparin (40 mg single dose) with apixaban (5 mg single dose), an additive effect on anti-Factor Xa activity was observed.
Croatian: Nakon kombinirane primjene enoksaparina (jedna doza od 40 mg) i apiksabana (jedna doza od 5 mg) uočen je aditivan učinak na aktivnost anti-faktora Xa.
English: Following surgery, other platelet aggregation inhibitors are not recommended concomitantly with Eliquis (see section 4.5).
Croatian: Nakon kirurškog zahvata ne preporučuje se istodobna primjena drugih inhibitora agregacije trombocita i lijeka Eliquis (vidjeti dio 4.5).
English: The concomitant use of Eliquis with antiplatelet agents increases the risk of bleeding (see section 4.5).
Croatian: Istodobna primjena lijeka Eliquis s antitrombocitnim lijekovima povećava rizik od krvarenja (vidjeti dio 4.5).
English: If necessary, your doctor may also give you the crushed Eliquis tablet mixed in 60 mL of water or 5% dextrose in water, through a nasogastric tube.
Croatian: Ako je potrebno, liječnik Vam može dati zdrobljene tablete Eliquis pomiješane sa 60 ml vode ili 5%tne otopine glukoze u vodi putem nazogastrične sonde.
English: A stroke can be life-threatening and requires immediate medical attention.
Croatian: Moždani udar može ugroziti život i stoga iziskuje hitnu medicinsku pomoć.
English: - Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing.
Croatian: - Alergijske reakcije (preosjetljivost) koje mogu izazvati: oticanje lica, usana, usta, jezika i/ili grla i otežano disanje.
English: - Film coat: lactose monohydrate, hypromellose (E464), titanium dioxide (E171), triacetin, yellow iron oxide (E172) See section 2 "Eliquis contains lactose (a type of sugar) and sodium".
Croatian: Film ovojnica: laktoza hidrat, hipromeloza (E464), titanijev dioksid (E171), triacetin, žuti željezov oksid (E172) Vidjeti dio 2 „Eliquis sadrži laktozu (jednu vrstu šećera) i natrij“.
English: Therefore, apixaban is not expected to alter the metabolic clearance of coadministered medicinal products that are metabolised by these enzymes.
Croatian: Stoga se ne očekuje da bi apiksaban mogao izmijeniti metabolički klirens istodobno primijenjenih lijekova koje navedeni enzimi metaboliziraju.
English: - to treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.
Croatian: - liječenje krvnih ugrušaka u venama nogu (duboka venska tromboza) i u krvnim žilama pluća (plućna embolija) te u sprječavanju ponovnog nastanka krvnih ugrušaka u krvnim žilama nogu i/ili pluća.
English: Included in this total were 1,262 patients (618 in the apixaban group) of age 75 or older, 1,004 patients (499 in the apixaban group) with low body weight (≤ 60 kg), 1,495 patients (743 in the apixaban group) with BMI ≥ 33 kg/m2, and 415 patients (203 in the apixaban group) with moderate renal impairment.
Croatian: U taj broj ulaze 1262 bolesnika (618 u skupini koja je uzimala apiksaban) u dobi od 75 ili više godina, 1004 bolesnika (499 u skupini koja je uzimala apiksaban) niske tjelesne težine (≤ 60 kg), 1495 bolesnika (743 u skupini koja je uzimala apiksaban) s BMI vrijednošću ≥ 33 kg/m2 i 415 bolesnika (203 u skupini koja je uzimala apiksaban) s umjerenim oštećenjem bubrežne funkcije.
English: Overdose of apixaban may result in a higher risk of bleeding.
Croatian: Predoziranje apiksabanom može povećati rizik od krvarenja.
English: Apixaban coadministered with clopidogrel (75 mg once a day) or with the combination of clopidogrel 75 mg and ASA 162 mg once daily, or with prasugrel (60 mg followed by 10 mg once daily) in Phase I studies did not show a relevant increase in template bleeding time, or further inhibition of platelet aggregation, compared to administration of the antiplatelet agents without apixaban.
Croatian: Istodobna primjena apiksabana i klopidogrela (75 mg jedanput na dan) ili kombinacije 75 mg klopidogrela i 162 mg ASK-a jedanput na dan, ili prasugrela (60 mg, nakon čega slijedi 10 mg jedanput na dan) u ispitivanjima faze I nije pokazala značajno produljenje vremena krvarenja ni dodatnu inhibiciju agregacije trombocita u usporedbi s primjenom antitrombocitnih lijekova bez apiksabana.
English: Eliquis can be taken with or without food.
Croatian: Eliquis se može uzimati s hranom ili bez nje.
English: In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20 mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively, and had no impact on Cmax.
Croatian: U zdravih ispitanika primjena aktivnog ugljena 2 sata i 6 sati nakon uzimanja doze apiksabana od 20 mg smanjila je prosječni AUC apiksabana za 50% odnosno 27% i nije utjecala na Cmax.
English: Electrical and/or pharmacologic cardioversion was conducted after at least 5 doses of 5 mg twice daily apixaban (or 2.5 mg twice daily in selected patients (see section 4.2)) or at least 2 hours after a 10 mg loading dose (or a 5 mg loading dose in selected patients (see section 4.2)) if earlier cardioversion was required.
Croatian: Električna i/ili farmakološka kardioverzija bila je provedena nakon najmanje 5 doza apiksabana od 5 mg dvaput na dan (ili 2,5 mg dvaput na dan u odabranih bolesnika (vidjeti dio 4.2)) ili, ako se s kardioverzijom nije moglo toliko čekati, najmanje 2 sata nakon udarne doze od 10 mg (ili udarne doze od 5 mg u odabranih bolesnika (vidjeti dio 4.2)).
English: The program was designed to demonstrate the efficacy and safety of apixaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and one or more additional risk factors, such as:
Croatian: Program je osmišljen da bi pokazao djelotvornost i sigurnost apiksabana u prevenciji moždanoga udara i sistemske embolije u bolesnika s nevalvularnom fibrilacijom atrija koji imaju još jedan dodatni čimbenik rizika, kao što je:
English: Apixaban efficacy in initial treatment of VTE was consistent between patients who were treated for a PE [Relative Risk 0.9; 95% CI (0.5, 1.6)] or DVT [Relative Risk 0.8; 95% CI (0.5, 1.3)].
Croatian: Djelotvornost apiksabana u početnom liječenju VTE bila je slična između bolesnika koji su liječeni od PE [Relativni rizik 0,9; 95% CI (0,5; 1,6)] ili DVT [Relativni rizik 0,8; 95% CI (0,5; 1,3)].
English: ¥ p-value < 0.0001 * For patients with more than one event contributing to the composite endpoint, only the first event was reported (e.g., if a subject experienced both a DVT and then a PE, only the DVT was reported) † Individual subjects could experience more than one event and be represented in both classifications
Croatian: U bolesnika s više od jednog događaja koji doprinosi kompozitnom ishodu, prijavljen je samo prvi događaj (npr., ako je ispitanik imao DVT i zatim PE, prijavljen je samo DVT) Pojedini ispitanici mogu imati više od jednog događaja i biti prikazani u objema klasifikacijama
English: Signs and symptoms of bleeding include bruising or bleeding under the skin, tar-coloured stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or weakness, sudden severe headache, coughing up blood or vomiting blood.
Croatian: Znakovi i simptomi krvarenja uključuju stvaranje modrica ili krvarenje ispod kože, crno obojenu stolicu, krv u mokraći, krvarenje iz nosa, omaglicu, umor, bljedilo ili slabost, iznenadnu tešku glavobolju, iskašljavanje krvi ili povraćanje krvi.
English: - Bleeding:
Croatian: - Krvarenje
English: Start treatment with Eliquis at the time you would have had the next dose of anticoagulant medicine, then continue as normal.
Croatian: Počnite liječenje lijekom Eliquis u vrijeme kad biste uzeli sljedeću dozu antikoagulansa, a zatim nastavite uzimati lijek kao i dotad.
English: Of the administered apixaban dose in humans, approximately 25% was recovered as metabolites, with the majority recovered in faeces.
Croatian: U čovjeka se otprilike 25% primijenjene doze pronađe u obliku metabolita, većinom u fecesu.
English: In a clinical trial of patients with atrial fibrillation, concomitant use of ASA increased the major bleeding risk on apixaban from 1.8% per year to 3.4% per year and increased the bleeding risk on warfarin from 2.7% per year to 4.6% per year.
Croatian: U kliničkom ispitivanju u bolesnika s fibrilacijom atrija istodobna primjena ASK-a povećala je rizik od velikog krvarenja kod primjene apiksabana s 1,8% na godinu na 3,4% na godinu te rizik od krvarenja kod primjene varfarina s 2,7% na godinu na 4,6% na godinu.
English: Table 2 shows the adverse reactions ranked under headings of system organ class and frequency using the following convention: very common (≥ 1/10) common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data) for NVAF and VTEt respectively.
Croatian: Tablica 2 prikazuje nuspojave kod NVAF i VTEt , razvrstane prema klasifikaciji organskih sustava i učestalosti u sljedeće kategorije: vrlo često (≥ 1/10); često (≥ 1/100 i < 1/10); manje često (≥ 1/1000 i < 1/100); rijetko (≥ 1/10 000 i < 1/1000); vrlo rijetko (< 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
English: If you stop taking Eliquis
Croatian: Ako prestanete uzimati Eliquis
English: Eliquis should be used with caution when coadministered with SSRIs/SNRIs or NSAIDs (including acetylsalicylic acid) because these medicinal products typically increase the bleeding risk.
Croatian: Potreban je oprez kod istodobne primjene lijeka Eliquis s SSRI-jevi/SNRI-jevi ili NSAIL-ovima (uključujući acetilsalicilatnu kiselinu), jer oni obično povećavaju rizik od krvarenja.
English: All-cause death occurred in 2 patients (0.27%) in the apixaban group and 1 patient (0.13%) in the heparin and/or VKA group.
Croatian: Smrt zbog bilo kojega razloga nastupila je u 2 bolesnika (0,27 %) u skupini liječenoj apiksabanom i u 1 bolesnika (0,13 %) u skupini liječenoj heparinom i/ili antagonistom vitamina K.
English: • The active substance is apixaban.
Croatian: • Djelatna tvar je apiksaban.
English: Major bleeding and CRNM bleeding events occurred in 3 (0.41%) and 11 (1.50%) patients, respectively, in the apixaban group, compared to 6 (0.83%) and 13 (1.80%) patients in the heparin and/or VKA group.
Croatian: Događaji velikih krvarenja i klinički značajnih, ali ne velikih krvarenja pojavili su se u 3 (0,41 %), odnosno 11 (1,50 %) bolesnika u skupini liječenoj apiksabanom, u usporedbi sa 6 (0,83 %) i 13 (1,80 %) bolesnika u skupini liječenoj heparinom i/ili antagonistom vitamina K.
English: Currently there is no experience with the use of recombinant factor VIIa in individuals receiving apixaban.
Croatian: Trenutno nema iskustva s primjenom rekombinantnog faktora VIIa u bolesnika koji primaju apiksaban.
English: For patients randomised to warfarin, the mean percentage of time in therapeutic range (INR 2.0-3.0) was 60.9.
Croatian: U bolesnika randomiziranih na varfarin, srednja vrijednost postotka vremena u terapijskom rasponu (INR 2,0-3,0) bila je 60,9%.
English: Coadministration of a single dose of apixaban (10 mg) and atenolol (100 mg), a common beta-blocker, did not alter the pharmacokinetics of atenolol.
Croatian: Istodobna primjena jedne doze apiksabana (10 mg) i atenolola (100 mg), uobičajenog beta-blokatora, nije izmijenila farmakokinetiku atenolola.
English: Therefore, apixaban does not inhibit P-gp mediated substrate transport.
Croatian: Stoga apiksaban ne inhibira transport supstrata u kojem posreduje P-gp.
English: There were no strokes (0%) in the apixaban group (n= 753) and 6 (0.80%) strokes in the heparin and/or VKA group (n = 747; RR 0.00, 95% CI 0.00, 0.64).
Croatian: Nije bio zabilježen niti jedan moždani udar (0 %) u skupini liječenoj apiksabanom (n = 753), dok je zabilježeno 6 (0,80 %) moždanih udara u skupini liječenoj heparinom i/ili antagonistom vitamina K (n = 747; relativni rizik 0,00; 95 % CI 0,00; 0,64).
English: Study treatment Dose
Croatian: Ispitivani lijek Doza
English: Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery (see section 5.1).
Croatian: Iako kod liječenja apiksabanom nije nužno rutinsko praćenje izloženosti, kalibrirani kvantitativni test anti-faktor Xa aktivnosti može biti koristan u iznimnim situacijama u kojima poznavanje informacije o izloženosti apiksabanu može pridonijeti donošenju kliničke odluke, npr. kod predoziranja ili hitnog kirurškog zahvata (vidjeti dio 5.1).
English: This condition (pulmonary embolism) can be life-threatening and requires immediate medical attention.
Croatian: Opisano stanje (plućna embolija) može biti opasno po život i iziskuje hitnu medicinsku pomoć.
English: • Concomitant treatment with any other anticoagulant agent e.g., unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2), when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation (see sections 4.4 and 4.5).
Croatian: • Istodobno liječenje bilo kojim antikoagulansom, npr. nefrakcioniranim heparinom, heparinima niske molekulske težine (enoksaparin, dalteparin itd.), derivatima heparina (fondaparinuks itd.), oralnim antikoagulansima (varfarin, rivaroksaban, dabigatran itd.), osim u posebnom slučaju promjene antikoagulantne terapije (vidjeti dio 4.2), kad se nefrakcionirani heparin daje u dozama nužnima za održavanje centralnog venskog ili arterijskog katetera otvorenim ili kada se nefrakcionirani heparin daje tijekom kateterske ablacije za fibrilaciju atrija (vidjeti dijelove 4.4 i 4.5).
English: These medicinal products may increase apixaban exposure by 2-fold (see section 4.5), or greater in the presence of additional factors that increase apixaban exposure (e.g., severe renal impairment).
Croatian: Ti lijekovi mogu povećati izloženost apiksabanu dvostruko (vidjeti dio 4.5) ili čak i više ako postoje dodatni čimbenici koji povećavaju izloženost apiksabanu (npr. teško oštećenje bubrežne funkcije).
English: In patients taking apixaban for the treatment of DVT and PE or prevention of recurrent DVT and PE, the results demonstrate a less than 2.2-fold fluctuation in peak-to-trough levels.
Croatian: U bolesnika koji uzimaju apiksaban za liječenje DTV i PE ili za prevenciju ponavljajućih DVT i PE, rezultati pokazuju da je fluktuacija između najviše i najniže razine manja od 2,2 puta.
English: These medicinal products may increase apixaban exposure by 2-fold (see section 4.5) or greater in the presence of additional factors that increase apixaban exposure (e.g., severe renal impairment).
Croatian: Ti lijekovi mogu dvostruko povećati izloženost apiksabanu (vidjeti dio 4.5) ili čak i više ako postoje dodatni čimbenici koji povećavaju izloženost apiksabanu (npr. teško oštećenje bubrežne funkcije).
English: Each 2.5 mg film-coated tablet contains 51.43 mg lactose (see section 4.4).
Croatian: Pomoćne tvari s poznatim učinkom Jedna filmom obložena tableta od 2,5 mg sadrži 51,43 mg laktoze (vidjeti dio 4.4).
English: Inhibitors of CYP3A4 and P-gp
Croatian: Inhibitori CYP3A4 i P-gp-a
English: Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery.
Croatian: Iako kod liječenja apiksabanom nije nužno rutinsko praćenje izloženosti, kalibrirani kvantitativni test anti-faktor Xa aktivnosti može biti koristan u iznimnim situacijama u kojima poznavanje informacije o izloženosti apiksabanu može pridonijeti donošenju kliničke odluke, npr. kod predoziranja ili hitnog kirurškog zahvata.
English: The incidence of ISTH major intraocular bleeding with apixaban was 0.18%/year.
Croatian: Incidencija velikog intraokularnog krvarenja prema ISTH kod primjene apiksabana iznosila je 0,18% na godinu.
English: Anti-Xa Activity Min (IU/mL)
Croatian: Najniža anti-Xa aktivnost apiksabana (IU/ml)
English: In subjects with end-stage renal disease (ESRD), the AUC of apixaban was increased by 36% when a single dose of apixaban 5 mg was administered immediately after haemodialysis, compared to that seen in subjects with normal renal function.
Croatian: U bolesnika u terminalnoj fazi bubrežne bolesti, AUC apiksabana povećao se za 36% kod primjene jednokratne doze od 5 mg apiksabana odmah nakon hemodijalize, u usporedbi s vrijednostima opaženih u ispitanika s normalnom bubrežnom funkcijom.
English: Other concomitant therapies
Croatian: Ostali istodobno primijenjeni lijekovi
English: Common reasons for unsuitability for VKA therapy in the AVERROES study included unable/unlikely to obtain INRs at requested intervals (42.6%), patient refused treatment with VKA (37.4%), CHADS2 score = 1 and physician did not recommend VKA (21.3%), patient could not be relied on to adhere to VKA medicinal product instruction (15.0%), and difficulty/expected difficulty in contacting patient in case of urgent dose change (11.7%).
Croatian: Uobičajeni razlozi zbog kojih terapija antagonistom vitamina K u ispitivanju AVERROES nije bila primjerena obuhvaćali su nemogućnost/malu vjerojatnost određivanja vrijednosti INR-a u zadanim intervalima (42,6%), bolesnikovo odbijanje liječenja antagonistom vitamina K (37,4%), rezultat na ljestvici CHADS2 = 1 zbog čega liječnik nije preporučio liječenje antagonistom vitamina K (21,3%), bolesnik nije pouzdan da će se pridržavati uputa za liječenje lijekom antagonistom vitamina K (15,0%) i poteškoće/očekivane poteškoće u kontaktiranju bolesnika u slučaju potrebe za hitnom promjenom doze (11,7%).
English: • Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 5.2).
Croatian: • Bolest jetre udružena s koagulopatijom i klinički značajnim rizikom od krvarenja (vidjeti dio 5.2).
English: Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets with 30 g of apple puree, the Cmax and AUC were 21% and 16% lower, respectively, when compared to administration of 2 whole 5 mg tablets.
Croatian: Nakon peroralne primjene 10 mg apiksabana u obliku 2 zdrobljene tablete od 5 mg s 30 g pirea od jabuka, Cmax i AUC iznosili su 21%, odnosno 16% manje, u usporedbi s primjenom 2 cijele tablete od 5 mg.
English: Instructions for crushing:
Croatian: Upute za drobljenje:
English: The overall incidence of adverse reactions related to bleeding with apixaban was 10% in the apixaban vs enoxaparin studies.
Croatian: Ukupna incidencija nuspojava povezanih s krvarenjem pri primjeni apiksabana bila je 10% u ispitivanjima apiksabana u odnosu na enoksaparin.
English: There was no impact of impaired renal function on peak concentration of apixaban.
Croatian: Oštećenje bubrežne funkcije nije imalo utjecaja na vršne koncentracije apiksabana.
English: Mean half-life of apixaban decreased from 13.4 hours when apixaban was administered alone to 5.3 hours and 4.9 hours, respectively, when activated charcoal was administered 2 and 6 hours after apixaban.
Croatian: Prosječni poluvijek apiksabana smanjio se s 13,4 sati kad je lijek primijenjen samostalno na 5,3 sati kod primjene aktivnog ugljena 2 sata nakon apiksabana, odnosno na 4,9 sati kod primjene aktivnog ugljena 6 sati nakon apiksabana.
English: If you forget to take Eliquis
Croatian: Ako zaboravite uzeti Eliquis
English: It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B) (see sections 4.2 and 5.2).
Croatian: Lijek treba primjenjivati uz oprez u bolesnika s blagim ili umjerenim oštećenjem jetrene funkcije (Child Pugh stadij A ili B) (vidjeti dijelove 4.2 i 5.2).
English: Alu PVC/PVdC perforated unit dose blisters of 60x1 and 100x1 film-coated tablets.
Croatian: Al PVC/PVdC perforirani blisteri s jediničnim dozama sa 60 x 1 i 100 x 1 filmom obloženom tabletom.
English: How to take Eliquis
Croatian: Kako uzimati Eliquis